Recombinant human endothelial cell growth factor
US5571790A · kind A · utility
3Cited by
12References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Nov 5, 1996 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.